Lumason® Infusion vs. Bolus Administrations

Exclusion Criteria

• •Patient has severe congestive heart failure (class IV according to the classification of the New York Heart Association);
• •Patient has uncontrolled angina (i.e., uncontrolled on medication);
• •Patient had a recent myocardial infarction (within the last 3 days and not stabilized);
• •Patient has severe arrhythmia, that in the opinion of the Investigator, would interfere with the study conduct;
• •Patient has severe pulmonary hypertension, that in the opinion of the Investigator, would interfere with the study conduct;
• •Patient had been treated with any other contrast medium, either intravascular or orally, within 48 hours prior to the first administration;
• •Has any known allergy to one or more of the ingredients of the investigational product;
• •Is pregnant or lactating. Exclude the possibility of pregnancy by: testing on site (serum or urine βHCG) prior to the start of investigational product administration; surgical history (e.g., tubal ligation or hysterectomy); post-menopausal with a minimum 1 year without menses;
• •Has previously entered the study or have received any other investigational drug within 30 days prior to admission in this study;
• •Is determined by the Investigator that the patient is clinically unsuitable for the study.